id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-337898-ncrbd8rp	Pal, Rimesh	Comment on “Is the type of diabetes treatment relevant to outcome of COVID‐19?”	2020-05-27		.txt	text/plain	1078	85	47	However, pioglitazone use is also associated with an increased risk of heart failure (HF) in patients with and without pre-existing cardiovascular disease [4] [5] [6] . Although pioglitazone does have anti-inflammatory properties independent of its glucose-lowering effect, it is debatable whether it would be of any benefit in COVID-19. Thus, in absence of robust clinical data favoring its use in either COVID-19 or T2DM, advocating hydroxychloroquine for its anti-inflammatory effects is certainly not wise. Pioglitazone Use and Heart Failure in Patients With Type 2 Diabetes and Preexisting Cardiovascular Disease: Data This article is protected by copyright. Effect of pioglitazone on heart function and N-terminal pro-brain natriuretic peptide levels of patients with type 2 diabetes Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19) The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas-a randomized trial	./cache/cord-337898-ncrbd8rp.txt	./txt/cord-337898-ncrbd8rp.txt